Suppr超能文献

双重靶向 AKT 和雷帕霉素靶蛋白:恶性外周神经鞘瘤的潜在治疗方法。

Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.

机构信息

Department of Surgical Oncology, The University of Texas M. D. AndersonCancer Center, Houston, Texas 77030, USA.

出版信息

Mol Cancer Ther. 2009 May;8(5):1157-68. doi: 10.1158/1535-7163.MCT-08-1008. Epub 2009 May 5.

Abstract

The mammalian target of rapamycin (mTOR) pathway may constitute a potential target for the treatment of malignant peripheral nerve sheath tumors (MPNST). However, investigations of other cancers suggest that mTOR blockade can paradoxically induce activation of prosurvival, protumorigenic signaling molecules, especially upstream AKT. Consequently, we hypothesized that dual phosphatidylinositol 3-kinase (PI3K)/AKT-mTOR blockade might be applicable for MPNST treatment. Expression of activated mTOR downstream targets (p4EBP1 and pS6RP) and pAKT was evaluated immunohistochemically in a tissue microarray of human MPNSTs (n = 96) and benign neurofibromas (n = 31). Results were analyzed by Wilcoxon rank-sum tests. mTOR and AKT pathways in human MPNST cell lines, and the effects of rapamycin (mTOR inhibitor), LY294002 (dual PI3K/mTOR inhibitor), and PI-103 (potent dual PI3K/AKT-mTOR inhibitor) on pathway activation were evaluated by Western blot. Effects on cell growth were evaluated via MTS and colony formation assays. Cell cycle progression and apoptosis were assessed by propidium iodide/fluorescence-activated cell sorting staining and Annexin V assays. Acridine orange staining/fluorescence-activated cell sorting analysis, electron microscopy, and Western blot evaluated autophagy induction. p4EBP1, pS6Rp, and pAKT levels were found to be significantly higher in MPNST versus neurofibroma (P < 0.05 for all markers). mTOR and AKT pathways were found to be highly activated in MPNST cell lines. MPNST cells were sensitive to rapamycin; however, rapamycin enhanced pAKT and peIF4E expression. PI-103 abrogated MPNST cell growth and induced G(1) cell cycle arrest potentially through repression of cyclin D1. PI-103 did not elicit apoptosis but significantly induced autophagy in MPNST cells. These results suggest further study of combined PI3K/AKT and mTOR inhibition as a novel therapy for patients harboring MPNST.

摘要

哺乳动物雷帕霉素靶蛋白(mTOR)通路可能是治疗恶性外周神经鞘瘤(MPNST)的潜在靶点。然而,对其他癌症的研究表明,mTOR 阻断剂可能会反常地诱导生存、促肿瘤信号分子的激活,尤其是上游 AKT。因此,我们假设双重磷脂酰肌醇 3-激酶(PI3K)/AKT-mTOR 阻断可能适用于 MPNST 的治疗。通过免疫组织化学方法在人类 MPNST(n=96)和良性神经纤维瘤(n=31)的组织微阵列中评估了激活的 mTOR 下游靶标(p4EBP1 和 pS6RP)和 pAKT 的表达。通过 Wilcoxon 秩和检验分析结果。通过 Western blot 评估了人 MPNST 细胞系中的 mTOR 和 AKT 通路,以及雷帕霉素(mTOR 抑制剂)、LY294002(双重 PI3K/mTOR 抑制剂)和 PI-103(有效的双重 PI3K/AKT-mTOR 抑制剂)对通路激活的影响。通过 MTS 和集落形成测定评估细胞生长的影响。通过碘化丙啶/荧光激活细胞分选染色和 Annexin V 测定评估细胞周期进程和细胞凋亡。吖啶橙染色/荧光激活细胞分选分析、电子显微镜和 Western blot 评估自噬诱导。与神经纤维瘤相比,MPNST 中的 p4EBP1、pS6Rp 和 pAKT 水平显著升高(所有标志物 P<0.05)。在 MPNST 细胞系中发现 mTOR 和 AKT 通路高度激活。MPNST 细胞对雷帕霉素敏感;然而,雷帕霉素增强了 pAKT 和 peIF4E 的表达。PI-103 阻断了 MPNST 细胞的生长,并通过抑制细胞周期蛋白 D1 诱导 G1 细胞周期停滞。PI-103 没有引发细胞凋亡,但显著诱导了 MPNST 细胞中的自噬。这些结果表明,进一步研究 PI3K/AKT 和 mTOR 抑制的联合应用作为一种新的治疗方法,用于携带 MPNST 的患者。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验